The detailed molecular mechanism of action of secondgeneration BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases. Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chemical proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel. The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/ threonine kinases. We have found clear differences in the target patterns of bosutinib in primary CML cells versus the K562 cell line. A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles. Common among those were the SRC, ABL and TEC family kinases. Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases. Although in vivo bosutinib is inactive against ABL T315I, we found this clinically important mutant to be enzymatically inhibited in the midnanomolar range. Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.
Introduction
Chronic myeloid leukemia (CML) is a three-phase hematopoietic disease originating in the stem cell compartment. A reciprocal translocation between chromosomes 9 and 22 results in the expression of the BCR-ABL fusion oncoprotein, a deregulated tyrosine kinase that activates several proliferative and antiapoptotic signaling pathways. 1 The BCR-ABL inhibitor imatinib (Gleevec, STI-571) entered the market in 2001 as the first targeted therapeutic against CML; 2 however, it soon became clear that both primary and secondary, or acquired, resistance toward imatinib can occur and thus necessitated the development of second-generation BCR-ABL inhibitors. 3, 4 Dasatinib (Sprycel, BMS-354825) and nilotinib (Tasigna, AMN107) are two such inhibitors that have been approved for the treatment of patients who are resistant or intolerant to imatinib. 5, 6 An up-and-coming next-generation BCR-ABL inhibitor is bosutinib (SKI-606), a dual Sarcoma/Abelson (SRC/ ABL) kinase inhibitor that has recently been introduced in clinical trials against CML (phase III) and breast cancer (phase II). [7] [8] [9] Bosutinib has been shown to target several imatinib resistance-causing BCR-ABL mutants, except the T315I mutant, and is unique in that it does not inhibit either the mast/stem cell (KIT) or platelet-derived (PDGFR) growth factor receptors, possibly explaining its higher therapeutic index. 7, 8 Furthermore, bosutinib results in a delayed compensatory upregulation in mitogen-activated protein kinase (MAPK) activity as compared with imatinib, suggesting further differences in their target profile. 10 Recent reports have demonstrated the success of large-scale profiling of kinase inhibitors to determine their full spectrum of target proteins in, for example, cell lines representing CML (K562) and breast cancer (Hs578T). [11] [12] [13] [14] [15] In our laboratory, we emphasize identifying drug targets in their clinically relevant patient cell populations. Thus, we previously used a chemical proteomic approach in which we immobilized coupleable analogs of imatinib, dasatinib and nilotinib and exposed them to total cell lysates not only of the BCR-ABL-positive K562 cell line, but also to extracts of primary CML patient cells, thereby identifying and subsequently validating both novel kinase (BTK, DDR1) and nonkinase (NQO2) targets. 14, 16 Here, we used a combined chemical proteomic and in vitro profiling method to evaluate (i) the natural target profile of bosutinib in primary CML and K562 cells and (ii) the activity of bosutinib versus dasatinib against over 270 recombinant kinases, thereby maximizing the cross-section of the kinome under investigation. This combined approach revealed that bosutinib, similar to dasatinib, is also a broad specificity kinase inhibitor, targeting not only SRC and ABL kinases, but also TEC family kinases, including BTK, which is known to have host immunomodulatory activity. 17 In contrast to dasatinib, bosutinib does not inhibit KIT or PDGFR, but rather displays a striking affinity toward the STE family of kinases, in particular the STE20 subfamily. CAMK2G, a Ca 2 þ /calmodulin-dependent protein kinase recently shown to be intricately involved in regulating signaling networks controlling the proliferation of myeloid leukemia cells, 18 was also identified as a novel kinase target inhibited by bosutinib, but not dasatinib. Furthermore, using chemical proteomics, clear differences were observed between the bosutinib target profiles within primary CML cells and the K562 cell line. In addition to the correlation found between inhibitor affinity purification and inhibition of kinase activity, this study exemplifies the complementary use of such kinase panels together with chemical proteomics for (near) kinomewide identification of possible targets that could be responsible for clinically observed (side) effects or represent secondary therapeutic points of intervention.
Materials and methods

Biological material
K562 cell pellets were generated by Cilbiotech (Mons, Belgium). Unfractionated peripheral blood leukocytes (buffy coat) were obtained from patients in accelerated-phase CML. Peripheral blood mononuclear cells were obtained using Ficoll. Studies were approved by the institutional review board (Medical University of Vienna). Written informed consent in accordance with the Declaration of Helsinki was obtained before blood donation.
Compounds and immobilization
Bosutinib was a gift from Oridis Biomed (Graz, Austria). c-Bosutinib was synthesized by Vichem Chemie Ltd (Budapest, Hungary) and acetylated or immobilized on NHS-activated Sepharose 4 Fast Flow (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) through its amino-functionality as described previously.
14 Dasatinib was synthesized by WuXi PharmaTech (Shanghai, China).
Kinase inhibition analysis
Bosutinib, c-bosutinib and its N-acetyl derivative were assayed in vitro for inhibition of recombinant full-length c-ABL (Millipore, Dundee, UK). Phosphorylation of 5FAM-KKGEAIYAAPFA-NH2 was monitored using the IMAP kinase assay kit and a SpectraMax M5 plate reader (Molecular Devices, Eugene, OR, USA). In addition, kinase assays were conducted using Millipore's KinaseProfiler according to the protocols detailed at http://www.millipore.com/drugdiscovery/dd3/ KinaseProfiler (see also the protocol manual supplied in Supplementary Figure S1 ), where adenosine triphosphate concentration for each specific kinase assay was set within 15 mM of the apparent Km for adenosine triphosphate where determined.
Affinity purification
Affinity chromatography was performed as described previously except that, in addition to our normal inhibitor mix, Roche's Complete Protease Inhibitor Cocktail tablet (1 tablet/50 ml lysis buffer) was included during experiments with the patients' cells. 14, 19 Sample preparation, mass spectrometry and mass spectrometry data processing See Supplementary Materials and methods.
Results and discussion
Chemical proteomics and kinase inhibition data sets display good correlation and complementarity
On the basis of the bosutinib binding mode to c-ABL and c-SRC, where the 4-methylpiperazine moiety is oriented toward the solvent region, 14, 20 the methyl group on the piperazine ring of bosutinib was replaced with a butylamine to form coupleable (c)-bosutinib ( Figure 1a) . Peripheral blood mononuclear cells were obtained from two CML patients with accelerated-phase disease upon clinical admission. Upon taking the blood samples, these patients had previously only received hydroxyurea, but no kinase inhibitor therapy (additional patient information, for example, blood makeup, is provided in Supplementary Table S1 ). In addition to the patient samples, K562 cells were used to allow for comparisons between the bosutinib profile obtained here and the profiles of bosutinib and other BCR-ABL inhibitors generated in this cell line. 11, 14 The list of identified proteins (Supplementary Tables S2-S4) obtained from cell lysates of the two CML patient samples and K562 following incubation with the bosutinib affinity matrix was filtered against a 'core proteome' data set (comprised of the most prevalent proteins in the total cell lysate of K562, for example, DNAPK, GCN1L1, HSPs, actin, tubulin) and a list of 'frequent hitters' (that is, nonspecific proteins, such as mTOR or COG6, identified in purifications using seven unrelated drugs).
14 Table 1 lists the protein kinases present in this filtered list (see also Supplementary Table S5 ).
In parallel to the chemical proteomic investigation, bosutinib and c-bosutinib were assayed at 1 and 10 mM against 272 recombinant kinases, including several clinically relevant kinase mutants (Supplementary Table S6 ). This analysis revealed a strong correlation (Po2.2E-16 for 1 mM and Po2E-16 for 10 mM) between inhibition by bosutinib and c-bosutinib further validating the use of c-bosutinib as a probe for detecting bosutinibbinding proteins in physiological samples (Figure 1b) . A correlation was also found between the two profiling techniques in that the stronger a kinase was purified using the chemical proteomic approach (that is, higher sequence coverage), the stronger it was found to be inhibited (that is, lower IC 50 ) in the kinase panel (Figure 1c) . Indeed, over half of the overlapping kinases were completely inhibited (less than 5% remaining activity) by 1 mM bosutinib. The three outliers, TAOK3, AMPK and MEK1, were still affected in a concentration-dependent manner, with less than 50% activity remaining at 10 mM. IC 50 values were also obtained for several kinases listed in Table 1 .
In addition to the significant link between kinase affinity purification and kinase activity inhibition, the complementary value of each technique was revealed, as several cell-type specific targets were only identified by affinity chromatography (see Table 1 ), while many additional targets of these drugs, probably not expressed in the cells used here, but important in terms of creating a comprehensive target profile, were revealed exclusively in the large-scale kinase inhibition assay ( Figure 1d ). Another benefit of this two-tiered approach is that the weakness of one technique is alleviated by the strength of the other. On the one hand, we have used a chemical proteomic method representing a post-genomic adaptation of classical drug affinity purification using high-end mass spectrometry and bioinformatics. The major advantage of this method when applied to disease-relevant cells is that a drug is exposed in an unbiased manner to the entire human proteome in a 'natural' setting. In contrast to most large-scale activity assays where recombinant proteins are used, this approach identifies drug-binding proteins in their natural state and environment, that is, level of abundance, post-translational modifications (for example, phosphorylation), splice variants and presence of natural binding partners. Such important considerations can all have a crucial impact on drug-protein interactions. However, the approach is only semiquantitative, as it does not directly allow for discrimination between affinity and abundance of the target, thus highlighting the synergistic potential for integration with a quantitative orthogonal approach as successfully shown by the recent kinobeads/iTRAQ approach, which measures protein binding competition. 11 In contrast, we here apply the abovementioned large-scale assays using recombinant kinases, which are advantageous in that (i) the inhibitory potential of the drug is determined quantitatively and directly on an enzymatic level and (ii) the panel of kinases is most likely different than the kinome expressed in the disease-related cells. Thus, quantitative data are also provided for 'off-target' kinases, which could be responsible for clinically observed side effects in other tissues or cell types or represent secondary therapeutic targets (Table 2  and Supplementary Table S7 ). There is a good correlation between the two different profiling techniques (less than 50% remaining activity at 1 mM (Po8.1E-9) for kinases seen in both assays). Differences are mainly attributable to the fact that chemical proteomics data imply, for example, also protein expression levels and post-translational modifications. The curve is drawn to suggest the logarithmic dependence of range of IC 50 with respect to the proteomics observations (sequence coverage) (curves of the form y ¼ ae Àbx , a, b40). Scatter plots were similar for all cell samples. Therefore, all proteomic observations were included in a single plot and each kinase is represented by several data points along its IC 50 depending on the number of cell samples in which it was observed. (d) The two techniques strongly complement each other as several targets are only identified using chemical proteomics (CP, black), whereas others are observed only in the kinase assay panel (KA, white). Gray circles represent kinases seen in both analyses. The Human Kinome Map is adapted with permission from Cell Signaling Technology (www.cellsignal.com).
Bosutinib potently inhibits not only the SRC and ABL family kinases, but also CAMK2G and the TEC and STE20 kinases
As expected, almost all SRC family kinases (SFKs) were identified with LYN (up to 58% sequence coverage), FGR and HCK, the three principle SFKs in myeloerythroid progenitor cells being most prominent (shown in bold in Table 1 ). The IC 50 for inhibition of all SFKs was less than 10 nM (see also Bantscheff et al. 11 ). The negative regulator of the SRC kinases, CSK, was also one of the top hits across all cell types (IC 50 ¼ 63 nM). ARG peptides and peptides mapping to both the BCR and ABL portions of BCR-ABL, resulting in a sequence coverage of 36%, were identified from K562 total cell lysates, thus serving as an important internal positive control. Despite high protease activity particularly affecting BCR-ABL in the primary CML patient cell lysates, 19 we were still able to identify ABL and ARG peptides in both patient samples. As with dasatinib, 13, 14, 16 the TEC family kinases are also prominently targeted by bosutinib, with three of five members identified. In particular, BTK (IC 50 ¼ 2.5 nM) was a major binding protein in all cell types. Thus, the use of bosutinib could result in effects on immune function. Other tyrosine kinases potently inhibited by bosutinib include the tumor suppressor EPHB4, FER, PTK2 (FAK), PYK2, SYK and TNK2, a nonreceptor protein tyrosine kinase whose overexpression in many human cancers is often associated with poor prognosis and knockdown of which leads to increased apoptosis in transformed cells. [21] [22] [23] In addition, several serine/ threonine kinases, for example, the NAK family members AAK1, BIKE and GAK, were identified.
Interestingly, the MAPK super family was found to be a major target group of bosutinib. Although MEK1 (and presumably also MEK2) is not significantly inhibited, the fact that bosutinib hits a combination of many other kinases in this pathway (for example, MST1 and GCK) could explain why, compared with imatinib, it exhibits a delayed increase in MAPK signaling in CML progenitor cells. 10, 24 Most remarkably, as many as 20 members of the STE group of serine/threonine kinases were found to interact with the bosutinib matrix, including 13 STE20 kinases. In this regard, five of the six STE20 kinases that were purified with the bosutinib matrix and included in the kinase assay have IC 50 values below 200 nM. Whereas the PAK subfamily of STE20 kinases does not seem to be sensitive toward bosutinib inhibition (IC 50 values greater than 1 mM for those tested), the GCK subfamily was significantly targeted. This subgroup of kinases is involved in the proapoptotic c-Jun N-terminal kinase and p38 MAPK signaling pathways, suggesting that bosutinib may actually also have antiapoptotic properties. However, the STE20 kinase most prominently identified, MST4 (sequence coverage of greater than 35% in the CML patient samples), has been indicated not only in proapoptotic signaling, as are the related MST1 and MST3 proteins, but also in upregulating proliferative and transformation signals. 25, 26 Moreover, it is unknown if the MSTs are active in these cells or if their proapoptotic activity is overruled by BCR-ABL signaling. Also part of the MAPK signaling pathway, but associated with antiapoptotic signaling, the TRKA and TRKB kinases were inhibited by bosutinib (IC 50 E25 nM) as well. These kinases are not only involved in neuronal development, but have also been shown to be either tumor supportive or suppressive, depending on the tumor type. 27 At this point, it is unclear what impact nanomolar inhibition of kinases involved in MAPK signaling by bosutinib will have on leukemic or healthy cells in CML therapy; however, this possibly complementary pro-(TRKs) and anti-(MSTs) apoptotic effect of bosutinib may be one aspect underlying the positive therapeutic index so far exhibited by bosutinib in clinical trials.
As in previous studies, we also identified several nonkinase proteins, such as GRB2, STS-1, SHC, NCK2 and SHIP2, which are known to interact with BCR-ABL and other tyrosine kinases and therefore are most likely to be copurified with these. 14 We furthermore detected some nonprotein kinases, such as pyruvate kinase and hexokinase-3, which upon further investigation turned out to be nonspecific binders, as their enzymatic activities were not inhibited by bosutinib (data not shown).
Finally and most notably, we have identified CAMK2G, a Ca 2 þ /calmodulin-dependent protein kinase recently shown to be involved in controlling myeloid leukemia cell proliferation, as a novel target inhibited by bosutinib (IC 50 ¼ 184 nM). 18 Hence, besides BCR-ABL and the SFKs, inhibition of CAMK2G is another important route through which bosutinib could exert its beneficial effect in CML. Furthermore, in contrast to other CAMK inhibitors, which interfere with Ca 2 þ /calmodulin complex formation, bosutinib represents, to our knowledge, the first compound directly targeting the adenosine triphosphate binding site of CAMK2G. This is an important aspect, as activated CAMK2G is relatively independent of levels of the Ca 2 þ / calmodulin complex. 18 Chemical proteomic approach discerns differences between primary patient and K562 cells
In this study, we have observed significant differences between the bosutinib protein target profiles in the K562 cell line versus the two primary patient cells, with the latter showing a much closer relationship to each other than to K562 (Figure 2) . K562, an established model cell line for CML most closely resembling blast crisis, is known to have alterations rendering it different from primary cell samples. 28, 29 Thus, several relevant targets would have been overlooked if only the K562 cell line was studied. For instance, numerous proteins were only identified in patient cells including 7 of the 13 STE20s, p38a, TNK2, the SFKs FGR and HCK and the TEC family kinase BMX. On the other hand, several kinases were purified on the bosutinib matrix only from K562 cells, namely PRKAA1 (AMPK), MAP2K5, MAP3K4, TEC and FAK. This disparity may highlight differences in protein expression, mutational status or differential secondary modifications affecting bosutinib binding. It is also possible that the proteins identified only in K562 cells do not actually play a role in the early stages of CML. Nonetheless, such proteins may still be of importance during blast crisis and/or present interesting targets for other disease manifestations. 
Biological pathway analysis of kinases inhibited by bosutinib emphasizes impact on MAPK signaling
To identify biological processes in the hematopoietic system that are particularly affected by bosutinib, we submitted all kinases identified through chemical proteomics to KEGG pathway analysis and scored the resulting pathways on the basis of the cumulative kinase IC 50 s, that is, the lower the IC 50 and therefore the higher the score, the stronger the pathway is considered affected by bosutinib. Using the above-mentioned correlation between sequence coverage and kinase inhibition (Figure 1c) , the IC 50 values were estimated for those kinases not included in the kinase assay panel. As expected, signal transduction and the immune system are highly represented among the top 10 KEGG pathways identified (Table 3) . Accordingly, MAPK signaling prominently heads the list with a score of 15.6 followed by Fc epsilon RI signaling and natural killer cell-mediated cytotoxicity. T-and B-cell receptor signaling are also among the top affected immune system pathways. Interestingly, the second highest hit pathway with a score of 12.4 is not involved in hematopoiesis, but rather in the regulation of the endocrine system. This possible influence on the gonadotropin-releasing hormone signaling pathway may hint at reproductive side effects in patients taking bosutinib.
Bosutinib protein target profile differs significantly from that of dasatinib
To allow for direct comparison between the global kinase profiles of bosutinib and dasatinib, both dual SRC/ABL inhibitors used against CML, dasatinib was also assayed against the kinase panel at 1 and 10 mM, and IC 50 values were determined for selected kinases for both drugs (Tables 1 and 2, Supplementary  Tables S6 and S7) . As with bosutinib, the IC 50 for inhibition of all SFKs for dasatinib is less than 10 nM (see also Bantscheff et al. 11 ). The TEC family kinases TEC, BTK and BMX are potently inhibited by both drugs (although slightly better by dasatinib). shows major differences to both CML patient cell samples as illustrated by the long dendrogram length. Peptide count increases from white (no peptides) to red. Heat map was obtained by using the square root of the average peptide count of each sample type and plotted with R (http://www.r-project.org) by using the Heatmap_2 package. Dendrograms are computed by using the Euclidean distance and averages. Square root was applied to scale the counts, and avoid dendrograms dominated by a few proteins only.
In agreement with the profiles obtained through chemical proteomics for dasatinib 14 and bosutinib, the kinase inhibition profile also illustrates that there are distinct differences in the kinases targeted by these two broad-spectrum SCR/ABL inhibitors ( Figure 3 ). This distinction seems to emphasize drug selectivity on the basis of the gatekeeper residue. For instance, whereas ABL (IC 50 o0.5 nM) and most of the assessed ABL mutants (H396P, M351T, Q252H and Y253F) were completely inhibited by both drugs at 1 mM, the ABL T315I mutant was, under applied assay conditions, inhibited by bosutinib almost 70 times more potently than by dasatinib (IC 50 of 26 versus 1648 nM, respectively), which curiously does not translate to cellular activity, as previous reports describe no effect of bosutinib on Ba/F3 cells, animal models or patients with the T315I mutation. 8, 30 The epidermal growth factor receptor gatekeeper mutant T790M was also more strongly inhibited by Figure 3 Targeting the kinome: bosutinib versus dasatinib. Emphasizing the differences found between bosutinib (red) and dasatinib (blue) as illustrated on the kinome tree. Purple circles represent kinases targeted by both drugs. Data points represent a compilation of targets obtained via chemical proteomics in K562 and CML patient cells, kinases inhibited at least 50% at 1 mM in the kinase panel (including AMPK, TAOK3 and MAP2K1, which were not sufficiently inhibited enzymatically, but still identified by chemical proteomics) and targets published by Bantscheff et al. 11 The Human Kinome Map is adapted with permission from Cell Signaling Technology (www.cellsignal.com).
bosutinib (IC 50 ¼ 491 nM) than by dasatinib (41% activity remaining at 10 mM). Thus, bosutinib may represent an interesting structural scaffold from which new inhibitors that are better able to target these clinically important mutants could be developed. Epidermal growth factor receptor was also inhibited to a higher degree by bosutinib (IC 50 ¼ 53 nM) than dasatinib (322 nM), which could have important implications for the use of bosutinib in additional (novel) indications, such as treatment of colorectal, pancreatic or nonsmall cell lung cancer. 31, 32 Further complementing the profiles obtained by chemical proteomics, dasatinib was far less active than bosutinib against the STE20s, which predominantly carry a methionine gatekeeper residue, exhibiting in most cases an IC 50 of greater than 10 mM for inhibition. As expected, neither KIT nor PDGFR are targeted by bosutinib; however, the FES tyrosine kinase, which is important for signaling by KIT D816V, 33 was inhibited, suggesting that despite resistance of this mutant to bosutinib, there may still be a clinical effect on D816V-positive malignancies. Finally, the Ca 2 þ /calmodulin-dependent protein kinases CAMK1D and CAMK2G, the neurotrophin-binding receptor tyrosine kinases TRKA/B and AXL, a recently reported target of bosutinib found to be involved in breast cancer cell motility and invasivity, 15 were selectively inhibited by bosutinib, whereas RIPK2 was inhibited only by dasatinib.
The different target profiles of bosutinib and dasatinib presented here may help in understanding some of the clinically observed side effects of these drugs. In particular, dasatinib inhibits both KIT and PDGFR, which are believed to play a role in the occurrence of serious pleural effusions frequently seen during dasatinib treatment. 34 Bosutinib, on the other hand, neither inhibits these kinases nor causes this particular side effect. However, inhibition of these two kinases alone cannot account for this effect, as they are also inhibited with similar potency by imatinib and nilotinib, which generally do not cause pleural effusions. 7 Therefore, a more complex explanation such as a combined inhibition of KIT or PDGFR and the TEC kinase BTK may be responsible. It is also possible that the receptor tyrosine kinase DDR1 plays a role in this regard. 14 
Conclusion
Bosutinib (SKI-606), originally designed as an SRC inhibitor, is also a potent ABL inhibitor and is at present in clinical trials for treatment of CML patients who are resistant or intolerant to imatinib therapy. 7, 35 In this study, we have shown the benefits of applying a two-tiered approach combining chemical proteomics and large-scale kinase inhibition analysis to establish a global protein target profile of bosutinib in a disease-relevant setting using cells obtained from patients with CML and the K562 cell line. Thus, we identified almost 20 new bosutinib kinase targets in CML patient cells. Overall, almost 50 novel targets were identified using the combined techniques.
Our approach illustrates the significant difference in target profiles from the experimental cell line K562 and the samples obtained from human patients, thus signifying the importance of generating such profiles in disease-specific primary cell populations. Furthermore, we have demonstrated a clear divergence of targets for bosutinib and dasatinib, including identifying several novel bosutinib targets, such as CAMK2G and the STE20 kinases. This aids in providing a molecular rationale for discriminating between these two rather broad specificity SRC/ ABL tyrosine kinase inhibitors in terms of the diverse clinical observations regarding both their efficacy and related side effects. It also helps to provide a basis for patient-specific use of such kinase inhibitors as single agents or in combination therapy against CML. logðIC 50ðiÞ =max IC 50 Þ for all kinases (i) we have identified in a pathway P. Unknown IC 50 s were estimated to be the median IC 50 of kinases with ±5% sequence coverage of the kinase of interest on the basis of the correlation seen between kinase purification through chemical proteomics (sequence coverage) and inhibition in kinase assays (IC 50 ) (Figure 1c ). Listed are those pathways involved in biological processes in the hematopoietic system. Although nonhematopoietic, GnRH signaling was the second top hit pathway identified and may hint at reproductive side effects in patients taking bosutinib.
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